ReviewInternational journal of nanomedicine2012
Inhaled chemotherapy in lung cancer: future concept of nanomedicine.
Review in International journal of nanomedicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review).International journal of oncology · 2024Pooled it
- Inhalable Nanomaterial Discoveries for Lung Cancer Therapy: A Review.Pharmaceutics · 2025Review
- Respiratory delivered vaccines: Current status and perspectives in rational formulation design.Acta pharmaceutica Sinica. B · 2024Review
- Nano-Formulations for Pulmonary Delivery: Past, Present, and Future Perspectives.Pharmaceutics · 2024Review
- Nebulisation of Paclitaxel, Sotatercept and Iloprost for pulmonary hypertension for lung cancer. FromJournal of Cancer · 2024Article
- Innovative Therapeutic Approaches Based on Nanotechnology for the Treatment and Management of Tuberculosis.International journal of nanomedicine · 2023Review
- Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments.Pharmaceutics · 2022Review
- Article
- Wasp venom peptide improves the proapoptotic activity of alendronate sodium in A549 lung cancer cells.PloS one · 2022Article
- Surface-engineered smart nanocarrier-based inhalation formulations for targeted lung cancer chemotherapy: a review of current practices.Drug delivery · 2021Review
- Recent Advances in Chronotherapy Targeting Respiratory Diseases.Pharmaceutics · 2021Review
- Modification of Apremilast from Pills to Aerosol a Future Concept.International journal of environmental research and public health · 2021Article
- Cytotoxicity, oxidative stress, and apoptosis in human embryonic kidney (HEK293) and colon cancer (SW480) cell lines exposed to nanoscale zeolitic imidazolate framework 8 (ZIF-8).Environmental science and pollution research international · 2021Article
- Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics.Advanced drug delivery reviews · 2021Review
- Pulmonary Delivery of Anticancer Drugs via Lipid-Based Nanocarriers for the Treatment of Lung Cancer: An Update.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Focused targeting of inhaled magnetic aerosols in reconstructed in vitro airway models.Journal of biomechanics · 2021Article
- Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus.Advanced therapeutics · 2021Review
- Sericin microparticles enveloped with metal-organic networks as a pulmonary targeting delivery system for intra-tracheally treating metastatic lung cancer.Bioactive materials · 2021Article
- Evaluation of the Physicochemical Properties, Pharmacokinetics, and In Vitro Anticancer Effects of Docetaxel and Osthol Encapsulated in Methoxy Poly(ethylene glycol)-International journal of molecular sciences · 2020Article
- Local Targeting of Lung-Tumor-Associated Macrophages with Pulmonary Delivery of a CSF-1R Inhibitor for the Treatment of Breast Cancer Lung Metastases.Molecular pharmaceutics · 2020Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regional chemotherapy was first used for lung cancer 30 years ago. Since then, new methods of drug delivery and pharmaceuticals have been investigated in vitro, and in animals and humans. An extensive review of drug delivery systems, pharmaceuticals, patient monitoring, methods of enhancing inhaled drug deposition, safety and efficacy, and also additional applications of inhaled chemotherapy and its advantages and disadvantages are presented. Regional chemotherapy to the lung parenchyma for lung cancer is feasible and efficient. Safety depends on the chemotherapy agent delivered to the lungs and is dose-dependent and time-dependent. Further evaluation is needed to provide data regarding early lung cancer stages, and whether regional chemotherapy can be used as neoadjuvant or adjuvant treatment. Finally, inhaled chemotherapy could one day be administered at home with fewer systemic adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.